Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat

Xtant Medical Holdings, Inc.

Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.
Hired approximately 20 Dilon U.S. sales personnel to commercialize the product.
HEMOBLAST Bellows is an FDA-approved collagen/thrombin/chondroitin sulfate hemostatic powder.
Addresses estimated $2.0 billion global addressable market for hemostatic products.
Xtant to update FY2026 guidance upon Q1 2026 earnings release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.